electrochemical skin conductance electrochemical skin conductance electrochemical skin conductance (esc) is an objective, non-invasive and quantitative electrophysiological measure. it is based on reverse iontophoresis and (multiple) steady chronoamperometry (more specifically chronovoltametry). esc is intended to provide insight into and assess sudomotor (or sweat gland) function and small fiber peripheral neuropathy. description of the esc measurement currently, esc measurement can be obtained with the use of a medical device, called sudoscan. no specific patient preparation or medical personnel training is required. the measure lasts less than 3 minutes, and is innocuous and non-invasive. the apparatus consists of stainless-steel electrodes for the hands and the feet which are connected to a computer for recording and data management purposes. to conduct an esc test, the patients place their hands and feet on the electrodes. sweat glands are most numerous on the palms of the hands and soles of the feet, and thus well suited for sudomotor function evaluation. the electrodes are used alternatively as anode or cathode. a direct current (dc) incremental voltage under 4 volts is applied on the anode. this dc, through reverse iontophoresis, induces a voltage on the cathode and generates a current (of an intensity less than 0.3 ma) between the anode and the cathode, related to electro-active ions from sweat reacting with the electrodes. the electrochemical phenomena are measured by the two active electrodes (the anode and the cathode) successively in the two active limbs (either hands or feet), whilst the two passive electrodes allow retrieval of the body potential. during the test, 4 combinations of 15 different low dc voltages are applied. the resulting electrochemical skin conductances (esc) for each hand and foot are expressed in µs (micro-siemens). the test also evaluates the percentage of asymmetry between the left and right side, for both hands and feet esc, providing an assessment of whether one side is more affected than the other. applications from a physiological standpoint, the pattern of innervation of the sweat gland—namely, the postganglionic sympathetic nerve fibers—allows clinicians and researchers to use sudomotor function testing to assess dysfunction of the autonomic nervous systems (ans). to ensure optimal use and interpretation of the esc, normative values were defined in adults and children. in addition, reproducibility of the method was assessed under clinical conditions, including both healthy controls and patients with common chronic conditions. esc has clinical utility in the evaluation and follow-up of dysautonomia and small fiber peripheral neuropathy which may occur in diseases such as: diabetes diabetes and two of its main complications: diabetic neuropathy and autonomic neuropathy. sensorimotor polyneuropathy (dspn) is the most common type of polyneuropathy in community-dwelling patients with diabetes, affecting about 25% of them. the course of dspn is insidious, though, and up to 50% of patients with neuropathy may be asymptomatic, often resulting in delayed diagnosis. advanced or painful dspn may result not only in reduced quality of life, but has been statistically associated with retinopathy and nephropathy, and leads to considerable morbidity and mortality. the autonomic nervous system (ans), of which sudomotor nerves are an integral part, is the primary extrinsic control mechanism regulating heart rate, blood pressure, and myocardial contractility. cardiac autonomic neuropathy (can) describes a dysfunction of the ans and its regulation of the cardiovascular system. can is the strongest predictor for mortality in diabetes. because early symptoms of can tend to be nonspecific, its diagnosis is frequently delayed and screening for can should be routinely considered in diabetic patients. assessment of sudomotor function provides a measure of sympathetic cholinergic function in the workup of can. amyloidosis amyloidosis such as familial amyloid neuropathy, al amyloidosis, and aa amyloidosis . during the course of al amyloidosis, peripheral neuropathy occurs in 10–35% of patients; dysautonomia itself is an independent prognostic factor, and assessment of sweat disturbances is routine in the evaluation of amyloidosis. esc may provide a measure of subclinical autonomic involvement, which is not systematically assessed with more sophisticated equipment. cystic fibrosis the effects of cystic fibrosis on sweat glands were described by quinton. the performance and potential utility of esc were assessed in this disease. parkinson’s disease assessment of dysautonomia is important for patient follow-up and assessment of sudomotor function can be helpful in daily practice. chemotherapy-induced peripheral neuropathy (cipn) chemotherapy-induced peripheral neuropathy is a common, potentially severe and dose-limiting adverse effect of multiple chemotherapeutic agents. cipn can persist long after the completion of chemotherapy and imposes a significant quality of life and economic burden to cancer survivors. esc allows for an objective quantification of small fiber impairment and is easy to implement in the clinic. sjögren syndrome esc may help in the diagnosis process. neuropathic pain neuropathic pain usually manifests in the setting of small fiber neuropathy. small fiber neuropathy is common and may arise from a number of conditions such as diabetes, metabolic syndrome, infectious diseases, toxins, and autoimmune disorders. the gold standard for diagnosing small fiber neuropathy as the etiology of neuropathic pain is skin biopsy. sudomotor assessment, an accurate objective technique, could be considered as a good screening tool to limit skin biopsy in patients in whom it is not suitable. esc has been evaluated for both early diagnosis of small fiber neuropathy and follow-up of treatment efficacy in each of these conditions. foundations: the eccrine sweat glands